Neuren Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is January - December.

Millions AUD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	217.19	213.24	231.93	14.55	-	0.72
Other Revenue	1.67	3.59	0.02	0.86	3.2	-
Revenue	218.86	216.83	231.94	15.42	3.2	0.72
Revenue Growth (YoY)	12.09%	-6.51%	1404.46%	382.23%	345.89%	44.85%
Cost of Revenue	29.98	32.97	26.75	12.71	9.52	7.76
Gross Profit	188.88	183.86	205.19	2.71	-6.32	-7.05
Selling, General & Admin	4.81	4.7	5.95	3.44	1.91	1.76
Operating Expenses	4.81	4.7	5.95	3.44	1.91	1.76
Operating Income	184.07	179.16	199.25	-0.73	-8.23	-8.81
Interest & Investment Income	11.47	11.01	5.69	0.39	0.04	0.15
Currency Exchange Gain (Loss)	-2.11	-7.24	2.43	1.23	0.4	-0.63
Other Non Operating Income (Expenses)	-2.62	-	-2.23	-0.7	-	0.1
EBT Excluding Unusual Items	190.82	182.94	205.14	0.18	-7.79	-9.19
Pretax Income	190.82	182.94	205.14	0.18	-7.79	-9.19
Income Tax Expense	41.76	40.9	48.06	-	-	-
Earnings From Continuing Operations	149.06	142.04	157.08	0.18	-7.79	-9.19
Net Income	149.06	142.04	157.08	0.18	-7.79	-9.19
Net Income to Common	149.06	142.04	157.08	0.18	-7.79	-9.19
Net Income Growth	27.08%	-9.57%	85270.11%	-	-	-
Shares Outstanding (Basic)	127	128	127	126	118	107
Shares Outstanding (Diluted)	130	131	131	129	119	107
Shares Change (YoY)	-0.98%	0.01%	1.44%	8.76%	10.71%	6.88%
EPS (Basic)	1.17	1.11	1.24	0.00	-0.07	-0.09
EPS (Diluted)	1.15	1.09	1.20	0.00	-0.07	-0.09
EPS Growth	28.33%	-9.58%	120020.00%	-	-	-
Free Cash Flow	137.56	-11.28	184.89	3.58	-9.98	-8.08
Free Cash Flow Per Share	1.06	-0.09	1.41	0.03	-0.08	-0.08
Gross Margin	86.30%	84.80%	88.47%	17.55%	-197.65%	-
Operating Margin	84.10%	82.63%	85.90%	-4.75%	-257.52%	-1228.59%
Profit Margin	68.11%	65.51%	67.72%	1.19%	-243.79%	-1282.15%
Free Cash Flow Margin	62.85%	-5.20%	79.71%	23.22%	-312.17%	-1127.48%
EBITDA	184.1	179.18	199.26	-0.72	-8.23	-8.8
EBITDA Margin	84.11%	82.64%	85.91%	-4.68%	-257.27%	-
D&A For EBITDA	0.02	0.02	0.02	0.01	0.01	0.01
EBIT	184.07	179.16	199.25	-0.73	-8.23	-8.81
EBIT Margin	84.10%	82.63%	85.90%	-4.75%	-257.52%	-
Effective Tax Rate	21.88%	22.36%	23.43%	-	-	-
Revenue as Reported	235.46	227.85	240.06	17.03	3.64	0.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.